Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 48,537 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AS+ Clear all

Conditions: Exercise, Health Behavior, Technology
Interventions: Focus Groups to Refine MobileMen App Content, Beta testing of MobileMen App Prototype; Behavioral
Lead sponsor: Klein Buendel, Inc.; Industry
Eligibility: 30 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 3
States / cities: Golden, Colorado • Washington D.C., District of Columbia • Baton Rouge, Louisiana

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 375,692 participants
Timeline: 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Firearm Injury, Pediatric Emergency Medicine, Suicide and Self-harm, Mental Health Issue
Interventions: Lethal means counseling, Provision of Cable-style gun locks; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV/AIDS
Interventions: Moxifloxacin, Placebo, Efavirenz; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stroke Hemorrhagic
Interventions: Surgical management, Medical Management; Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 19 more

Conditions: HIV Infections, Sexually Transmitted Diseases, Stigma, Social
Interventions: Information Resources, Social Support, HIV Testing; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 15 Years to 29 Years · Male only
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Diabetic Foot Ulcer
Interventions: Celliant Diabetic Medical Socks, Control (placebo) Medical Socks; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 22 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions: BI 10773, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 18
States / cities: Anaheim, California • Lomita, California • Plantation, Florida + 15 more

Conditions: Coronary Artery Disease
Interventions: [O-15]-Water PET Myocardial Perfusion Imaging (MPI); Drug
Lead sponsor: MedTrace Pharma A/S; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Iowa City, Iowa • Rochester, Minnesota • St Louis, Missouri + 3 more

Conditions: Adenocarcinoma of the Ovary
Interventions: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine; Biological
Lead sponsor: AVAX Technologies; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 3
States / cities: Zion, Illinois • Tulsa, Oklahoma • Philadelphia, Pennsylvania

Conditions: Substance Use Disorder (SUD)
Interventions: Community Restitution Apprenticeship-Focused Training (CRAFT), Standard Employment Model; Other
Lead sponsor: West Virginia School of Osteopathic Medicine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lewisburg, West Virginia

Conditions: HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Interventions: Denikitug, Nivolumab, Ramucirumab, Paclitaxel; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: Boston, Massachusetts • Albany, New York • New York, New York

Conditions: Multiple Myeloma
Interventions: Supportive Care (home-based physical activity), Exercise Intervention, telephone interview, Remote Monitoring, Patient Monitoring, Questionnaire Administration, Electronic Health Record Review; Behavioral · Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)
Interventions: 5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days, Azacitidine (AZA), Cytarabine (Ara-C), Anthracycline; Diagnostic Test · Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Refractive Errors, Astigmatism
Interventions: Verofilcon A toric contact lenses, Stenfilcon A toric contact lenses; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 6
States / cities: Maitland, Florida • Pittsburg, Kansas • Sterling Heights, Michigan + 3 more

Conditions: Suicide
Interventions: Continuous Identity Cognitive Therapy (CI-CT), General Health Education; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Smoking Cessation
Interventions: Smoking Cessation Counseling; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Alzheimer's Disease
Interventions: I-123-MNI-168, 123-I MNI-168; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 50 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Kidney Failure
Interventions: Vfend®; I.V.; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 6
States / cities: New Orleans, Louisiana • Minneapolis, Minnesota • Knoxville, Tennessee + 1 more

Conditions: Melanoma
Interventions: Vemurafenib, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 47
States / cities: Birmingham, Alabama • California City, California • Hayward, California + 38 more

Conditions: Hypertension, Vitamin D Deficiency, Pre-Hypertension
Interventions: Cholecalciferol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 534 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Hartford, Connecticut • Boston, Massachusetts • Minneapolis, Minnesota

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Paclitaxel, Carboplatin, Bevacizumab, IMNN-001; Drug
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Baltimore, Maryland • New York, New York • Oklahoma City, Oklahoma + 1 more

Conditions: Multi-Drug Resistant Organism
Interventions: Allogeneic Microbiota in Glycerol (10%) (AMG); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Cirrhosis
Interventions: selenium, placebo; Dietary Supplement
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Physical Activity Smartphone App for African American Men (FitBros) Phase I

Preop COVID Testing Patterns

Randomized Trial to Improve Safe Firearm Storage

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

Rapid Evacuation and Access of Cerebral Hemorrhage Trial

Increasing Engagement and Improving HIV Outcomes Via HealthMPowerment

Celliant Socks to Increase Tissue Oxygenation and Complete Wound Closure in Diabetic Foot Wounds

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

Recovery Works - Facilitating Sustainable Recovery Through Workforce

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Clinical Comparison of 2 Daily Disposable Toric Soft Contact Lenses

Development of a Recovery Oriented Treatment for Post-Acute Suicidal Episode (PASE) Veterans

Smoking Cessation Study

Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

DAYLIGHT: Vitamin D Therapy in Individuals at High Risk of Hypertension

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Sentinel Cohort REACT

Selenium Supplementation of Patients With Cirrhosis